Skip to content
MARKETS / AVCRF
PHARMACEUTICAL PREPARATIONS · SMALL CAP

Avricore Health Inc. AVCRF

10 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 4.7M
▲ 33.7% YoY
CAD -668,977
CAD 823,521
In brief

What this company does

Through its flagship offering HealthTab™ (a wholly owned subsidiary), it provides a turnkey point-of-care testing platform, creating value for stakeholders and better outcomes for patients. This is all possible thanks to the Company’s HealthTab™ technology, which provides lab-accurate results for specific blood work within 12 minutes. The Company is also in late-stage discussions with other Canadian and international major pharmacy chains, and has a strong prospect list for future expansion.

Written from the business description in Avricore Health Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 June 2025. Every sentence was checked against that document before publication.

Growth
CAD 4.7M
Revenue, FY2024 · full 10-year series below
Revenue CAD M Net income CAD M
FY2024 · Revenue 4.7 · Net income -0.7
2M4M-2M-4M2014201620172018201920202021202220232024
Compound annual growth
+236.0%
+95.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−14 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -14.4%
-10000%-20000%-30000%2014201620172018201920202021202220232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2024 · FCF 0.8
0.4M0.8M-0.8M-1.6M2014201620172018201920202021202220232024

Total assetsCAD 2.3M
CashCAD 1.1M
DepositsCAD 12,000.00

Not available: we don't have the total debt figure for this period.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162014
Revenue CAD B0.00.00.00.00.0·0.00.00.00.0
Operating income CAD B··········
EBITDA CAD B··········
Income tax CAD B··········
Net income CAD B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow CAD B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted CAD −0.01−0.01−0.01−0.02······
Dividend / sh CAD ··········
Payout %··········
ROE %··········

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures · 4 divergences in 43 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures4 divergent
ActivityPharmaceutical Preparations
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image